Introduction
Mammalian gastrointestinal tracts (GIT) are densely colonized with a multitude of bacterial species.
In humans, bacterial cells and genes outnumber their human counterparts by a factor of 10 and 100, respectively [1] [2] [3] . Commensal bacteria are not randomly or evenly distributed in the GIT [4] [5] [6] , and studies have suggested that we coevolved with our microbiota [7] . This complex community of bacteria is beneficial to us, as dysbiosis, or altered microbiota, correlates with an increased susceptibility to infection and higher incidence of inflammatory processes such as metabolic syndrome, diabetes, allergy, and inflammatory bowel disease (IBD) [8] . Further, commensals can prevent infectious disease by competing with pathogens for nutrients, limiting pathogen binding sites, and producing anti-microbial factors such as bacteriocins [9] . Beneficial microbes also affect host health by regulating intestinal permeability and modulating host responses [10, 11] . Our knowledge of how gastrointestinal microbes and their products modulate immune cells has begun to blossom. Although gut microbes produce a variety of molecules that alter host immune function, here we focus on bacterial EPSs with known in vivo effects and discuss their role in host health.
Exopolysaccharides and Immunomodulation
EPSs are secreted heterogeneous structures produced by a variety of bacteria which may or may not be surface REVIEW associated. EPSs are comprised of repeating mono-or oligosaccharides linked by various glycosidic linkages, and the three dimensional structures and other physiochemical features of EPSs can vary widely. This variability could in part explain the different immunomodulatory properties of beneficial microbes as described below. The immunomodulatory role of EPSs in bacterial pathogenesis has been appreciated for many years and has been reviewed extensively [12] [13] [14] . EPSs from pathogens can, e.g., regulate cytokine production, contribute to bacterial adherence to host cells, and inhibit phagocytosis [15, 16] . Here we will focus on EPSs from beneficial microbes and how they affect cells of the innate and adaptive immune systems to protect the host. B. fragilis, an anaerobic, Gram negative autochthonous organism, is present in mammalian gastrointestinal tracts. B. fragilis makes 8 polysaccharides (A-G) with polysaccharide A (PSA) being the most abundant [17] . PSA is comprised of an unusual repeating tetrasaccharide
) and has free carboxyl, phosphate, and amino groups that contribute to its zwitterionic nature, which is important for its function [18, 19] . Native PSA is approximately 130 kDa, but larger moieties of the repeating tetrasaccharide are needed to elicit immune responses [20] . Several studies have elegantly elucidated how PSA and B. fragilis alter DC and T cell populations. B. fragilis, present in the mucus that overlays epithelial cells, secretes outer membrane vesicles containing PSA that are taken up by DCs [21] . It is unclear if DCs sample PSA-containing outer membrane vesicles directly from the lumen or if B. fragilis and/or these vesicles travel through M cells to reach the underlying DCs. PSA then induces the development of plasmacytoid DCs which requires both TLR2 and Growth Arrest and DNA-Damage-Inducible protein (Gadd45α) [21, 22] . These DCs produce cytokines including IL-12, TNF-, and IFN- in a TLR2-dependent manner, thus altering the cytokine milieu in vivo [23] . DCs also process PSA via the endocytic pathway and present deaminated shorter PSA derivatives to T cells via MHCII molecules [19] . Carbohydrates are typically considered T cell-independent antigens and the presentation of PSA on MHCII molecules is unusual and dependent on both the N-linked glycosylation and zwitterionic nature of PSA.
In additional to modulating DCs, administration of PSA to either germfree or conventionally reared mice alters T cell populations ( Figure 1A) . In germfree mice, administration of PSA or PSA-producing B. fragilis results in expansion of splenic CD4 + T cells, but not CD19 + B cells or CD8 + T cells [24] . This study with B. fragilis was one of the first to show that a single commensal species could partially restore the stunted systemic immune system of germfree mice. These changes are not limited to germfree mice and a similar expansion of splenic CD4 + T cells was observed in conventionally reared mice treated with PSA [24] . PSA also skews CD4 + T cell subsets in conventionally reared mice. Administration of PSA strains expands proinflammatory Th17 populations and limits the colonization of this mutant [25] . In contrast, PSA-producing B. fragilis or PSA alone does not result in expanded Th17 cells, but in the generation of anti-inflammatory IL-10-producing, Foxp3 + Treg cells and allows for the persistence of B. fragilis [25] [26] [27] . Treg cells that develop in response to B. fragilis and PSA treatment appear functional and reportedly both prevent and attenuate chemically-induced colitis and experimental autoimmune encephalomyelitis (EAE) in mice [28, 29] . These studies demonstrate that commensal exopolysaccharides possess wide-ranging therapeutic potential.
Early studies suggested that purified PSA induced IL-10 production by CD4 + T cells in a TLR2-dependent manner [25, 29] ; however, in a recent study, when CD4 + T cells were incubated with PSA-containing outer membrane vesicles, likely more physiologically relevant than purified PSA, they did not produce IL-10 [21, 29] . Collectively, these data suggest that in vivo, rather than PSA directly inducing Treg cells, PSA-containing outer membrane vesicles are processed by DCs, which then present PSA derivatives to T cells on MHCII molecules, and thereby promote the development of anti-inflammatory Treg cells.
Interestingly, similar changes in Treg cell populations have been observed when mice are treated with Bifidobacter breve or a cocktail of commensal Clostridial species. B. breve activates intestinal DCs to produce IL-10 and IL-10-producing Treg cells which prevent colitis that develops in a T cell transfer model of IBD [30] . Mice treated with Clostridial species also generate colonic IL-10-producing Treg cells and are protected from allergic diarrhea, and from colitis induced by dextran sodium sulfate (DSS) and trinitrobenzenesulfonate (TNBS) [29, 31] . Although the bacterial molecules responsible for protection by B. breve or Clostridial species were not identified in these studies, like PSA of B. fragilis, TLR2 signaling was required for B. breve-mediated protection [30] . These data suggest that bacterial EPSs may act as TLR ligands, leading to an anti-inflammatory response. Collectively, the studies with B. fragilis, Clostridial species and B. breve highlight how commensal bacteria can regulate intestinal homeostasis and ameliorate disease via IL-10-producing Treg cells and in a TLR2-dependend manner. By promoting development of anti-inflammatory intestinal Treg cells, these autochthonous organisms may persist in high numbers and/or as long-term colonizers in the colon without inducing a damaging inflammatory response.
Immunomodulation by Bacillus subtilis EPS: Macrophages
Our lab has studied the beneficial role of the intestinal microbiota for years and recently, we showed that a single dose of B. subtilis prevents enteric inflammatory disease in mice infected with Citrobacter rodentium [32] . C. rodentium is an attaching and effacing murine pathogen that associates intimately with the epithelium to induce colitis in a manner similar to the human pathogen, enteropathogenic E. coli [33, 34] . We initially speculated that B. subtilis prevented disease by forming a protective gastrointestinal biofilm which would limit host: pathogen interactions. To test this idea, we used biofilm mutants, predicting that these mutants would not prevent C. rodentium-induced disease. Surprisingly, some biofilm mutants were protective and others were not, even though all of the mutants tested were present at levels comparable to wild type [32] . All protective strains were capable of producing EPS as part of their biofilm matrix, leading us to suggest that EPS is the protective molecule of B. subtilis. Consistent with this idea, we purified EPS from a B. subtilis strain that overproduced soluble EPS and found that it alone was sufficient to prevent disease [35] . Carbohydrate analysis revealed that B. subtilis EPS is comprised of 3 sugars, mannose (88%), glucose (11.9%) and N-acetyl-glucosamine (<0.1%) with linkages as described [35] . The composition of this EPS contrasts with that reported previously [34] , and additional studies are needed to identify which sugar moieties and linkages are critical for protection.
Because B. subtilis did not interfere with pathogen colonization or alter intestinal barrier function [33] , we hypothesized that EPS-mediated protection was a result of immune modulation and we have begun to search for cells and host signaling pathways involved. We found that EPS, which is administered intraperitoneally, bound F4/80 + CD11b + peritoneal macrophages [35] . The transfer of macrophage-rich peritoneal cells from an EPS-treated mouse to naïve mice prevented infectious colitis in recipient mice infected with C. rodentium. Further, EPStreated mice that lack MyD88 signaling in myeloid cells developed disease when infected with C. rodentium, supporting the role of macrophages in EPS-mediated protection [35] .
Bacterial and fungal carbohydrates are ligands for TLRs, and we hypothesized that TLR signaling may be required for protection by B. subtilis EPS. We tested this idea using MyD88
-/-and TLR4 -/-mice and found that all of these strains were susceptible to C. rodentium after EPS treatment and were not protected from inflammatory disease ( [35] and unpublished data). These data suggest that signaling through both TLR2 and TLR4 is important for protection. Through adoptive transfer studies, we showed that TLR4 signaling is required by macrophage-rich peritoneal cells [35] and that TLR2 signaling is required on an unidentified second cell (unpublished data) ( Figure 1B) . Interestingly, Hayashi et al. [35] recently demonstrated that probiotic Clostridium butyricum promoted the development of anti-inflammatory IL-10-producing F4/80 + CD11b + CD11c int macrophages via TLR2 and that these cells were critical for preventing DSS-induced colitis [36] . Although the protective factor from C. butyricum has not been identified, the mechanism of protection by this probiotic treatment has similarity to that of B. subtilis EPS (myeloid involvement) and PSA (TLR2). Also of note, both Bacillus and Clostridial species are spore-forming bacteria and spores may occupy a different GIT niche or be processed differently than vegetative bacteria by immune cells, e.g., macrophages or DCs.
Immunomodulation by Other Bacterial EPSs: B cells
One potential therapeutic use for probiotics is as a mucosal adjuvant, and several studies recently reported the effects of EPSs from beneficial microbes on B cell populations and antibody production ( Figure 1C and D). As described above, B. breve is a commensal organism of the GIT and a well-studied probiotic that can prevent colitis in a T cell transfer model of colitis [37] . Fanning et al. [37] identified two operons that regulate EPS production. These operons are adjacent and oppositely-oriented with a shared promoter between them. The promoter is flanked on either side by a nearly identical 75bp inverted repeat, suggesting that a DNA recombinase/invertase may regulate the orientation of the EPS promoter as observed with capsule production in other species. Consistent with this idea, the authors only observe transcription from either the EPS1 or EPS2 operon, and the promoter is oriented differently in each case. The composition, structure and size of these EPSs is not known. This study also examined the role of EPS in host immunomodulation by using B. breve EPS + and EPS -mutants. Mice treated with EPS -strains had more plasma cells and higher quantities of B. breve specific IgG and IgA than did mice that received EPS + strains [38] . Both EPS -and EPS + B. breve strains initially colonize well, but over time colonization of the EPS -mutants decreased in the cecum and feces. In contrast, EPS + and EPS -strains both persisted in B cell-deficient mice [38] , suggesting that EPS affects adaptive immune responses, in this case by downregulating the generation of B. breve-specific antibodies that would clear this organism from its intestinal niche.
Another B cell-modulating EPS has been isolated from kefir, a fermented milk drink cultured using a variety of lactic acid producing bacteria, yeast, and acetic acidproducing bacteria [39] . Some bacteria in kefir are encased in an EPS dubbed kefiran. Kefiran isolated from Lactobacillus kefiranofaciens is comprised of equal amounts of glucose and galactose and has a molecular weight >10 7 Da [40] . To assess if kefiran from L. kefiranofaciens has immunomodulatory activity, Vinderolaet al. [41] isolated and administered kefiran to mice in their drinking water and observed an increase in the number of IgA + B cells in the small and large intestine as soon as 2 days post kefiran treatment [41] . Additionally, more colonic IgG + cells were observed in kefiran-treated mice at 2, 5, and 7 days after treatment when compared to controls. Kefiran treatment also resulted in changes in serum IL-4, IL-6, IL-10, and IFN, but not TNF or IL-12 [41] . Interestingly, Madrano et al. [42] also observed an increase in peritoneal and lamina propria F4/80 + macrophages in mice fed kefiran. These data and those described above with B. fragilis PSA highlight how mucosal application of bacterial products can have both local and systemic effects on several types of immune cells. Several studies have examined the beneficial effects of kefir on cancer [42] and high blood pressure [43] ; future studies are needed to assess if kefiran is responsible for the health promoting ability of kefir and to elucidate the host pathways involved.
EPS from B. breve inhibits antibody production, while EPS from L. kefiranofaciens promote immunoglobulinproducing cells. Why do EPSs have such different effects on antibody production? One possibility is that commensal organisms like B. breve have evolved factors to limit host immune responses such as antibody production that would interfere with their persistence in the GIT. Consistent with this idea, B cell-deficient mice were colonized equally with EPS + and EPS -strains, but colonization of the EPS -strain decreased in wild type mice over time [38] . In contrast, transient microbes such as L. kefiranofaciens that do not permanently colonize may not have evolved molecules to promote their persistence.
Molecular mechanisms of protection
We now know that EPSs from beneficial microbes in the GIT alter both innate and adaptive immune cells (summarized in Figure 1) ; however, large gaps in our understanding of how these EPSs function still exist. Importantly, are there receptors for bacterial EPSs which upon interaction with EPS transmit signals that alter immune function, or are EPSs endocytosed and then immune cell function is altered intracellularly? Several studies have demonstrated the necessity for TLR2 and TLR4 signaling [22, 25, 30, 35] , and potentially, some EPSs bind TLR molecules. Cell surface TLR signaling complexes are comprised of multiple proteins, including Ctype lectins, which could also serve as EPS receptors and modulate cytokine production [44, 45] . Signaling via DC-SIGN, a C-type lectin, regulates DC maturation and subsequent T cell polarization, which may contribute to the immune response elicited by PSA [46] . Additionally, Lactobacillus reuteri and Lactobacillus casei utilize DC-SIGN on DCs to induce T regulatory cells; however the essential ligands produced by these probiotics are unknown [47] . Mannose binding proteins are also attractive candidate receptors, especially for B. subtilis EPS, which is comprised mostly of mannose [35] .
If EPSs are recognized by receptors on the surface of immune cells, what are the downstream signaling molecules altered by the addition of EPSs? Many C-type lectins signal through immunoreceptor tyrosine-based activation motif (ITAM) and immunoreceptor tyrosinebased inhibitory motif (ITIM) [48] , making these attractive candidates as signaling molecules to investigate. Signaling through ITAMs induces an array of cellular responses, including cell proliferation, differentiation, migration and phagocytosis. Activation of Src family kinases or Syk kinase through ITAM-like motifs activates a network of signaling pathways, including MAPK and NF- pathways [49] . In contrast, signaling through ITIM-like motifs negatively regulates the activity of many signaling pathways, including TLRs and other PRRs, by recruiting tyrosine phosphatases. C-type lectins do not signal exclusively through ITIM or ITAM-like motifs and have been shown to modulate a number of other signaling cascades [48] , which may account for the diverse effects of these receptors.
How do EPS-induced changes alter immune cell populations and/or function? Viruses, bacteria, and fungi have been shown to bind DC-SIGN, and modulate TLR signaling by activating the serine/threonine kinase Raf-1, leading to acetylation of the p65 subunit of NF-, and ultimately enhancing anti-inflammatory cytokine production [50] . In addition to NF- other transcriptional factors such as PPAR-, NFAT, and AP-1 could regulate the beneficial changes induced by EPSs in vivo. Fungal EPSs activate PPAR- [51] and development of antiinflammatory immune cells such as M2 macrophages is PPAR- dependent [52] . We suggest that some EPSs such as those isolated from B. subtilis may alter PPAR- activity and promote development of anti-inflammatory macrophages, which suppress inflammation. Additionally, PPAR- has been shown to inhibit NF--dependent transcriptional activation, which may account for antiinflammatory effects of PPAR- signaling [53, 54] . Signaling through C-type lectins alters the function and/or location of the transcription factors NF-, NFAT, and AP-1.We hypothesize that EPSs from beneficial microbes may be recognized by C-type lectins on the surface of immune cells; that binding of EPSs to receptors results in changes to cell signaling molecules and transcription factors; and these EPS-induced cellular changes result in the altered cytokine milieu in vivo that promotes immune homeostasis.
The in vivo molecular targets of the bacterial EPSs discussed so far are not known. However in vitro studies using EPSs derived from other bacteria, even those which are not present in mammalian GITs, may offer insights into the receptors of and signaling pathways modulated by EPSs. For example, Lin et al. [55] published an in vitro study using TA-1, an EPS from the Gram-negative, rod-shaped thermophile Thermus aquaticus and showed that incubation of high quantities of TA-1 with murine RAW 264.7 macrophages or peritoneal macrophages resulted in NF- activation and production of pro-inflammatory TNF- and IL-6 [55] . This inflammatory response was dependent on TLR2, suggesting that TA-1, which is comprised of tetrasaccharide-repeating units of galactofuranose, galactopyranose, and Nacetylgalactosamine (1:1:2) acts as a TLR2 ligand [55] , and mediates its response through NF- Although T. aquaticus is not a mammalian commensal, it functions via TLR2, similar to PSA from B. fragilis and EPS from B. subtilis.
Since PSA and B. subtilis EPS suppress inflammation, these molecules may alter host immune responses by suppressing, rather than activating the NF- signaling pathway. Cell signaling processes are complex and after we identify the cells modulated by EPSs, we can begin to explore the internal changes that occur in these cells and expand our molecular understanding of how EPSs promote health.
Summary and Future studies
Studies on EPSs from beneficial microbes are relatively recent, and future experiments can be expected to shed exciting insights into the mechanisms of EPS: host interactions that are not only responsible for developing and maintaining immune homeostasis, but also provide therapeutic opportunities. Clearly, additional studies are needed to elucidate the structure and composition of immunomodulatory EPSs. Although this review has focused on bacterial EPSs, it is not surprising that diverse bacterial factors may contribute to host health given the complexity of the commensal microbiota. Studies on other immunomodulatory molecules will be essential to better understand the complex nature of host: microbial interactions and how beneficial microbes can be used as therapeutic agents. For example, sphingolipids from B.
fragilis restrict the development of invariant natural killer cells (iNKT) which protect neonatal mice from chemically induced colitis [56] . Interestingly, modulation of iNKT cells is limited to neonatal mice, since sphingolipids did not limit iNKT numbers or provide protection from colitis in older mice [56] . This study highlights how some bacterial immunomodulatory factors function in developmental windows and the same may be true for some bacterial EPSs. In many cases, we do not know if immunomodulation by EPSs is transient or permanent. If we understood the developmental windows in which the host is responsive to EPSs, as well as the kinetics of EPS immunomodulatory activity, we could rationally apply beneficial microbes to treat diseases.
For most studies, it is not known if EPSs act directly or indirectly on the immune system. One mechanism by which EPSs could indirectly modulate immune responses is by contributing to production of short chain fatty acids such as butyrate. Butyrate contributes to intestinal permeability, and low butyrate levels result in a leaky gut [57] , which could alter the access of microbial associated molecular patterns to immune cells and alter inflammatory processes. Further, fermentation of complex carbohydrates in the cecum and colon by Clostridial species resulted in butyrate and induction of Treg cells [57, 58] . Previously, Sonnenburg et al. (2005) demonstrated that Bacteroides thetaiotamicron scavenges host carbohydrates from mucus as an energy source when other carbon sources are scarce [59] ; we hypothesize that bacterial EPSs could also be scavenged and fermented by competing microbes, thereby indirectly modulating host immune responses. Studies elucidating the direct and indirect effects of EPS treatment; identifying host EPS receptors; determining how EPSs are processed in vivo; and investigating the mechanism involved in the age-specificity of some probiotics could provide valuable insights which would allow translation of probiotics developed in mouse models to human patients. As our knowledge of EPS-elicited immune changes expands, we should be able to develop better probioticderived therapeutics to prevent and attenuate human maladies.
